OCALA, Fla., Oct. 09, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), announced today that Tom Equels, Chief Executive Officer of AIM, will participate in a ...

OCALA, Fla., Sept. 30, 2024 (GLOBE NEWSWIRE) -- (NYSE American: AIM) (“AIM” or the “Company”) today announced that it has ...

This in turn suggests a coherent picture of the structural organization of many dsRNA viruses. We present structures of a type 5 CPV determined by cryo-EM, revealing striking similarities with ...

The Company’s lead product is a first-in-class investigational drug called Ampligen ® (rintatolimod), a dsRNA and highly ...

Yes, the nose is often the first point of initial contact with the microbial world. That was certainly the lesson of COVID and helped to explain all those nasal swabbings.

AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the United States Patent and Trademark Office (USPTO) has granted U.S. patent No. 12,102,649, covering both ...

The innate immune system recognizes microorganisms by pattern-recognition receptors (PRRs), which are germline-encoded, limited in number and have a broad specificity against conserved molecular ...

In collaboration with Laszlo Farkas (VCU), we showed that deficiency of the pattern recognition receptor (TLR3) exacerbated pulmonary hypertension, while activating TLR3 (using synthetic ...

Expert Rev Vaccines. 2012;11(1):55-67. A summary of the events taking place after intradermal injection of naked mRNA is given inFigure 1. Although formulation of mRNA vaccines and sophisticated ...

The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in ...

The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in ...